Rubén Burgos-Vargas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rubén Burgos-Vargas has a total of 398 co-authors. Here are the top co-authors by number of shared publications:
- Janitzia Vázquez-Mellado
J. Vázquez-Mellado, MD, PhD, Department of Rheumatology, Hospital General de México and Faculty of Medicine, Universidad Nacional Autónoma de México, Mexico City, Mexico
9 shared publications - Ingris Peláez-Ballestas
Rheumatology Unit, Hospital General de Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico
7 shared publications Janitzia Vázquez-Mellado
6 shared publications- Walter Maksymowych
Department of Medicine University of Alberta Edmonton Alberta Canada
6 shared publications - Nicolino Ruperto
Dipartimento di Medicina e Chirurgia, Università degli Studi di Milano-Bicocca, Milano, Italy
5 shared publications - Amita Aggarwal
Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
4 shared publications
Latest Publications
- Open Access
- 1 March 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
Clinical Expression of Radiographic Axial Spondyloarthritis and Its Association With HLA-B27 in European and Ibero-American Populations
J Rheumatol 2025; doi:10.3899/jrheum.2024-1085The funding statement has been revised to the following: "This study was partially funded by the SER-GRESSER/JANSSEN grant, with no involvement from Janssen in its development."This correction applies only to the February 15 2025 First Release. The correct text appears in the print and online issues.
- 1 March 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
Open AccessClinical Expression of Radiographic Axial Spondyloarthritis and Its Association With HLA-B27 in European and Ibero-American Populations
J Rheumatol 2025; doi:10.3899/jrheum.2024-1085The funding statement has been revised to the following: "This study was partially funded by the SER-GRESSER/JANSSEN grant, with no involvement from Janssen in its development."This correction applies only to the February 15 2025 First Release. The correct text appears in the print and online issues.
- 4 February 2025
- Published by Wiley in Arthritis Care & Research
- Vol. 77 (6) , 785-791
Do the Provisional Paediatric Rheumatology International Trials Organisation Enthesitis/Spondylitis‐Related Juvenile Idiopathic Arthritis Criteria Capture Youth With Axial Spondyloarthritis?
Objective: The Paediatric Rheumatology International Trials Organisation (PRINTO) recently undertook an effort to better harmonize the pediatric and adult arthritis criteria. These provisional criteria are being refined for optimal performance. We aimed to investigate differences between patients who did and did not fulfill these PRINTO criteria among youth diagnosed with juvenile spondyloarthritis (SpA) that met axial juvenile SpA (axJSpA) classification criteria.Methods: This was a retrospective cross‐sectional sample of youth diagnosed with juvenile SpA who met the axJSpA classification criteria. Demographics, clinical manifestations, and physician and patient‐reported outcomes were abstracted from medical records. Magnetic resonance imaging (MRI) scans underwent central imaging review by at least two central raters. Differences between groups were compared using Wilcoxon signed‐rank test or chi‐square test, as appropriate.Results: Of 158 patients who met axJSpA criteria, 107 patients (68%) met the PRINTO provisional criteria for enthesitis/spondylitis‐related arthritis. A total of 41 patients (26%) did not fulfill any of the three major PRINTO criteria due to lack of peripheral disease manifestations. Demographics, prevalence of inflammatory or structural lesions on MRI, family history of SpA, and duration of pain were not statistically different between those who did and did not meet PRINTO criteria. Those who fulfilled the PRINTO criteria had significantly more peripheral arthritis, enthesitis, and HLA‐B27 positivity but reported less sacral/buttock pain.Conclusion: Phenotypic differences of children with axJSpA between those who were and were not classified by the PRINTO criteria were primarily due to peripheral disease manifestations and HLA‐B27 positivity. Modification of the PRINTO provisional criteria may facilitate capture of youth with primarily axial disease.
- 4 February 2025
- Published by Wiley in Arthritis Care & Research
- Vol. 77 (6) , 785-791
Do the Provisional Paediatric Rheumatology International Trials Organisation Enthesitis/Spondylitis‐Related Juvenile Idiopathic Arthritis Criteria Capture Youth With Axial Spondyloarthritis?
Objective: The Paediatric Rheumatology International Trials Organisation (PRINTO) recently undertook an effort to better harmonize the pediatric and adult arthritis criteria. These provisional criteria are being refined for optimal performance. We aimed to investigate differences between patients who did and did not fulfill these PRINTO criteria among youth diagnosed with juvenile spondyloarthritis (SpA) that met axial juvenile SpA (axJSpA) classification criteria.Methods: This was a retrospective cross‐sectional sample of youth diagnosed with juvenile SpA who met the axJSpA classification criteria. Demographics, clinical manifestations, and physician and patient‐reported outcomes were abstracted from medical records. Magnetic resonance imaging (MRI) scans underwent central imaging review by at least two central raters. Differences between groups were compared using Wilcoxon signed‐rank test or chi‐square test, as appropriate.Results: Of 158 patients who met axJSpA criteria, 107 patients (68%) met the PRINTO provisional criteria for enthesitis/spondylitis‐related arthritis. A total of 41 patients (26%) did not fulfill any of the three major PRINTO criteria due to lack of peripheral disease manifestations. Demographics, prevalence of inflammatory or structural lesions on MRI, family history of SpA, and duration of pain were not statistically different between those who did and did not meet PRINTO criteria. Those who fulfilled the PRINTO criteria had significantly more peripheral arthritis, enthesitis, and HLA‐B27 positivity but reported less sacral/buttock pain.Conclusion: Phenotypic differences of children with axJSpA between those who were and were not classified by the PRINTO criteria were primarily due to peripheral disease manifestations and HLA‐B27 positivity. Modification of the PRINTO provisional criteria may facilitate capture of youth with primarily axial disease.
- 15 January 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (2) , 165-172
Effect of Characteristic Inflammatory and Structural Pelvic Magnetic Resonance Imaging Lesions on Expert Assessment of Axial Juvenile Spondyloarthritis
Objective: To evaluate the influence of pelvic magnetic resonance imaging (MRI) findings on axial disease assessment in juvenile spondyloarthritis (JSpA).Methods: This was a cross-sectional study of patients with JSpA with suspected axial disease. Three experts reviewed each case and rated their confidence (–3 to +3) in the presence of axial disease, first with clinical data and second with clinical and MRI data. Agreement was defined as ≥ 2/3 clinical experts with a rating of ≤ –1 or ≥ 1, and high confidence agreement as ≤ –2 or ≥ 2. The association of clinical features and both global assessments was tested with modified Poisson regression models.Results: Two hundred seventy-two of 303 cases (89.8%) achieved agreement with clinical data alone. Adding imaging data affected agreement in 38.9% (118/303) and directionality of agreement in 23.4% (71/303). Agreement was facilitated in 26/31 cases and lost in 21/272 cases. Of those 71 cases that changed directionality, 33 changed from axial disease being absent to present and 38 from present to absent. The final model had an area under the receiver-operating characteristic (AUROC) curve of 0.93 and 3 factors were independently associated with expert agreement (HLA-B27: relative risk [RR] 1.41, 95% CI 1.14-1.74; pain improvement with activity: RR 1.27, 95% CI 1.05-1.54; and bone marrow edema on MRI: RR 4.08, 95% CI 2.91-5.73).Conclusion: The addition of imaging data affected directionality and improved high confidence agreement of expert assessment of axial disease. These results underscore the integral role of MRI in the determination of axial disease in JSpA.
- 15 January 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (2) , 165-172
Effect of Characteristic Inflammatory and Structural Pelvic Magnetic Resonance Imaging Lesions on Expert Assessment of Axial Juvenile Spondyloarthritis
Objective: To evaluate the influence of pelvic magnetic resonance imaging (MRI) findings on axial disease assessment in juvenile spondyloarthritis (JSpA).Methods: This was a cross-sectional study of patients with JSpA with suspected axial disease. Three experts reviewed each case and rated their confidence (–3 to +3) in the presence of axial disease, first with clinical data and second with clinical and MRI data. Agreement was defined as ≥ 2/3 clinical experts with a rating of ≤ –1 or ≥ 1, and high confidence agreement as ≤ –2 or ≥ 2. The association of clinical features and both global assessments was tested with modified Poisson regression models.Results: Two hundred seventy-two of 303 cases (89.8%) achieved agreement with clinical data alone. Adding imaging data affected agreement in 38.9% (118/303) and directionality of agreement in 23.4% (71/303). Agreement was facilitated in 26/31 cases and lost in 21/272 cases. Of those 71 cases that changed directionality, 33 changed from axial disease being absent to present and 38 from present to absent. The final model had an area under the receiver-operating characteristic (AUROC) curve of 0.93 and 3 factors were independently associated with expert agreement (HLA-B27: relative risk [RR] 1.41, 95% CI 1.14-1.74; pain improvement with activity: RR 1.27, 95% CI 1.05-1.54; and bone marrow edema on MRI: RR 4.08, 95% CI 2.91-5.73).Conclusion: The addition of imaging data affected directionality and improved high confidence agreement of expert assessment of axial disease. These results underscore the integral role of MRI in the determination of axial disease in JSpA.
- 15 January 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (5) , 450-459
Clinical Expression of Radiographic Axial Spondyloarthritis and Its Association With HLA-B27 in European and Ibero-American Populations
Objective: To compare the clinical and sociodemographic characteristics of Ibero-American patients with radiographic axial spondyloarthritis (r-axSpA) to those of European patients with r-axSpA, with a particular focus on the influence of HLA-B27. Methods: This was an observational, cross-sectional, and multicenter study of patients who fulfilled the European Spondyloarthropathy Study Group criteria for SpA from the Registry of Spondyloarthritis of Spanish Rheumatology (REGISPONSER) and Ibero-American Registry of Spondyloarthropathies (RESPONDIA). Univariate and multivariate analyses between European and Ibero-American populations stratified by HLA-B27 status were conducted. Race stratification (White, Black American, and American Indian) was also performed to evaluate clinical differences according to HLA-B27. Results: A total of 2592 patients with a clinical diagnosis of r-axSpA were included in the analysis: 1083 (41.8%) Ibero-American patients and 1509 (58.2%) European patients. Among the patients who were HLA-B27 positive, Ibero-American status was independently associated with conventional synthetic disease-modifying antirheumatic drug (csDMARD) intake (odds ratio [OR] 4.21), arthritis (OR 2.33), enthesitis (OR 6.01), dactylitis (OR 6.10), severe structural damage (Bath Ankylosing Spondylitis Radiological Index [BASRI]; OR 1.12), and poor functionality (Bath Ankylosing Spondylitis Functional Index; OR 1.40). Multivariate analysis of patients who were HLA-B27 negative revealed that Ibero-American status was independently associated with enthesitis (OR 11.67), csDMARDs (OR 15.51), and total BASRI (OR 1.34). Clinical manifestations also varied across racial groups, with differences noted in the prevalence of peripheral joint manifestations, such as more arthritis and enthesitis in American Indian patients than in White and Black American patients. Conclusion: Ibero-American patients with r-axSpA in our study exhibit more peripheral manifestations, more structural damage, and worse functionality than European patients, regardless of the presence of HLA-B27.
- 15 January 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (5) , 450-459
Clinical Expression of Radiographic Axial Spondyloarthritis and Its Association With HLA-B27 in European and Ibero-American Populations
Objective: To compare the clinical and sociodemographic characteristics of Ibero-American patients with radiographic axial spondyloarthritis (r-axSpA) to those of European patients with r-axSpA, with a particular focus on the influence of HLA-B27. Methods: This was an observational, cross-sectional, and multicenter study of patients who fulfilled the European Spondyloarthropathy Study Group criteria for SpA from the Registry of Spondyloarthritis of Spanish Rheumatology (REGISPONSER) and Ibero-American Registry of Spondyloarthropathies (RESPONDIA). Univariate and multivariate analyses between European and Ibero-American populations stratified by HLA-B27 status were conducted. Race stratification (White, Black American, and American Indian) was also performed to evaluate clinical differences according to HLA-B27. Results: A total of 2592 patients with a clinical diagnosis of r-axSpA were included in the analysis: 1083 (41.8%) Ibero-American patients and 1509 (58.2%) European patients. Among the patients who were HLA-B27 positive, Ibero-American status was independently associated with conventional synthetic disease-modifying antirheumatic drug (csDMARD) intake (odds ratio [OR] 4.21), arthritis (OR 2.33), enthesitis (OR 6.01), dactylitis (OR 6.10), severe structural damage (Bath Ankylosing Spondylitis Radiological Index [BASRI]; OR 1.12), and poor functionality (Bath Ankylosing Spondylitis Functional Index; OR 1.40). Multivariate analysis of patients who were HLA-B27 negative revealed that Ibero-American status was independently associated with enthesitis (OR 11.67), csDMARDs (OR 15.51), and total BASRI (OR 1.34). Clinical manifestations also varied across racial groups, with differences noted in the prevalence of peripheral joint manifestations, such as more arthritis and enthesitis in American Indian patients than in White and Black American patients. Conclusion: Ibero-American patients with r-axSpA in our study exhibit more peripheral manifestations, more structural damage, and worse functionality than European patients, regardless of the presence of HLA-B27.
- 8 September 2024
- Published by Wiley in Arthritis & Rheumatology
- Vol. 76 (12) , 1797-1808
Classification Criteria for Axial Disease in Youth With Juvenile Spondyloarthritis
Objective: The goal was to develop and validate classification criteria for axial juvenile spondyloarthritis (SpA; AxJSpA).Methods: This international initiative consisted of four phases: (1) item generation, (2) item reduction, (3) criteria development, and (4) validation of the AxJSpA criteria by an independent team of experts in an internationally representative validation cohort.Results: These criteria are intended to be used on youth with a physician diagnosis of juvenile SpA and for whom axial disease is suspected. Item generation consisted of a systematic literature review and a free‐listing exercise using input from international physicians, which collectively resulted in 108 items. After the item reduction exercise and expert panel input, 37 items remained for further consideration. The final AxJSpA criteria domains included the following: imaging of active inflammation, imaging of structural lesions, pain chronicity, pain pattern, pain location, stiffness, and genetics. The most heavily weighted domains were active inflammation and structural lesions on imaging. Imaging typical of sacroiliitis was deemed necessary, but not sufficient, to classify a youth with AxJSpA. The threshold for classification of AxJSpA was a score of ≥55 (out of 100). When tested in the validation data set, the final criteria had a specificity of 97.5% (95% confidence interval [CI] 91.4%–99.7%), sensitivity of 64.3% (95% CI 54.9%–73.1%), and area under the receiver operating characteristic curve of 0.81 (95% CI 0.76%–0.86%).Conclusion: The new AxJSpA classification criteria require an entry criterion and a physician diagnosis of juvenile SpA and include seven weighted domains. The AxJSpA classification criteria are validated and designed to identify participants for research studies. image
- 8 September 2024
- Published by Wiley in Arthritis & Rheumatology
- Vol. 76 (12) , 1797-1808
Classification Criteria for Axial Disease in Youth With Juvenile Spondyloarthritis
Objective: The goal was to develop and validate classification criteria for axial juvenile spondyloarthritis (SpA; AxJSpA).Methods: This international initiative consisted of four phases: (1) item generation, (2) item reduction, (3) criteria development, and (4) validation of the AxJSpA criteria by an independent team of experts in an internationally representative validation cohort.Results: These criteria are intended to be used on youth with a physician diagnosis of juvenile SpA and for whom axial disease is suspected. Item generation consisted of a systematic literature review and a free‐listing exercise using input from international physicians, which collectively resulted in 108 items. After the item reduction exercise and expert panel input, 37 items remained for further consideration. The final AxJSpA criteria domains included the following: imaging of active inflammation, imaging of structural lesions, pain chronicity, pain pattern, pain location, stiffness, and genetics. The most heavily weighted domains were active inflammation and structural lesions on imaging. Imaging typical of sacroiliitis was deemed necessary, but not sufficient, to classify a youth with AxJSpA. The threshold for classification of AxJSpA was a score of ≥55 (out of 100). When tested in the validation data set, the final criteria had a specificity of 97.5% (95% confidence interval [CI] 91.4%–99.7%), sensitivity of 64.3% (95% CI 54.9%–73.1%), and area under the receiver operating characteristic curve of 0.81 (95% CI 0.76%–0.86%).Conclusion: The new AxJSpA classification criteria require an entry criterion and a physician diagnosis of juvenile SpA and include seven weighted domains. The AxJSpA classification criteria are validated and designed to identify participants for research studies. image
- 5 July 2024
- Published by Springer Nature in Clinical Rheumatology
- Vol. 43 (8) , 2627-2636
Peripheral neuropathy in patients with gout, beyond focal nerve compression: a cross-sectional study
Neuropathies secondary to tophus compression in gout patients are well known; however, limited data exist on other types of peripheral neuropathies (PN). O
- 5 July 2024
- Published by Springer Nature in Clinical Rheumatology
- Vol. 43 (8) , 2627-2636
Peripheral neuropathy in patients with gout, beyond focal nerve compression: a cross-sectional study
Neuropathies secondary to tophus compression in gout patients are well known; however, limited data exist on other types of peripheral neuropathies (PN). O
- Open Access
- 6 May 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-8
Differences between radiographic and non-radiographic axial spondyloarthritis patients in a Mexican cohort
To compare the demographic, clinical, and laboratory characteristics, disease onset, and clinical features of radiographic axial Spondyloarthritis (r-axSpA) and non-radiographic axial Spondyloarthritis (nr-axSpA) patients. All patients who attended outpatient spondylarthritis (SpA) clinics at Hospital General de Mexico and the Instituto Nacional de la Nutrición from 1998 to 2005 and met the rheumatologist diagnostic criteria for SpA were selected. Then the SpA patients were classified by European Spondyloarthropathy Study Group criteria (ESSG). We selected SpA patients with axial presentation as axial SpA (axSpA), and they were classified as r-axSpA if they met modified New York (mNY) criteria for sacroiliitis and as nr-axSpA if they did not meet mNY criteria; to compared clinical, demographic, and laboratory test between the subgroups. It included 148 SpA patients; 55 (37.2%) patients had r-axSpA, and 70 (47.3%) had nr-axSpA. The nr-axSpA patients had a lower proportion of males (58.6% vs 78.2%, P < 0.05), lower HLA-B27 frequency (54.3%. vs. 92.7%, P < 0.05), were older at disease onset (21 vs 16 years; P < 0.01) and had a higher frequency of infections at disease onset (9.1% vs 32.9, P < 0.05) than r-axSpA. BASFI (2.9 vs 4.8; P < 0.0001), Dougados functional index (7 vs. 14; P < 0.05), and BASDAI (4.1 vs. 5.2; P < 0.001) were lower in patients with nr-axSpA than r-axSpA, respectively. The factors that most influenced the presentation of r-axSpA were history of uveitis (OR 14, 95% CI 2.3–85), HLA-B27 (OR 7.97, 95% CI, 2.96–122), male sex (OR 6.16, 95% CI, 1.47–25.7), axial enthesopathy count (OR 1.17 95% CI, 1.03–1.33). This study provides insight into the differences between nr-axSpA and r-axSpA in Mexico. Patients with r-axSpA were mainly male, with a younger presentation age, a higher prevalence of HLA-B27, more history of uveitis, fewer episodes of dactylitis, more axial enthesopathy, and higher disease activity than nr-axSpA.
- 6 May 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-8
Open AccessDifferences between radiographic and non-radiographic axial spondyloarthritis patients in a Mexican cohort
To compare the demographic, clinical, and laboratory characteristics, disease onset, and clinical features of radiographic axial Spondyloarthritis (r-axSpA) and non-radiographic axial Spondyloarthritis (nr-axSpA) patients. All patients who attended outpatient spondylarthritis (SpA) clinics at Hospital General de Mexico and the Instituto Nacional de la Nutrición from 1998 to 2005 and met the rheumatologist diagnostic criteria for SpA were selected. Then the SpA patients were classified by European Spondyloarthropathy Study Group criteria (ESSG). We selected SpA patients with axial presentation as axial SpA (axSpA), and they were classified as r-axSpA if they met modified New York (mNY) criteria for sacroiliitis and as nr-axSpA if they did not meet mNY criteria; to compared clinical, demographic, and laboratory test between the subgroups. It included 148 SpA patients; 55 (37.2%) patients had r-axSpA, and 70 (47.3%) had nr-axSpA. The nr-axSpA patients had a lower proportion of males (58.6% vs 78.2%, P < 0.05), lower HLA-B27 frequency (54.3%. vs. 92.7%, P < 0.05), were older at disease onset (21 vs 16 years; P < 0.01) and had a higher frequency of infections at disease onset (9.1% vs 32.9, P < 0.05) than r-axSpA. BASFI (2.9 vs 4.8; P < 0.0001), Dougados functional index (7 vs. 14; P < 0.05), and BASDAI (4.1 vs. 5.2; P < 0.001) were lower in patients with nr-axSpA than r-axSpA, respectively. The factors that most influenced the presentation of r-axSpA were history of uveitis (OR 14, 95% CI 2.3–85), HLA-B27 (OR 7.97, 95% CI, 2.96–122), male sex (OR 6.16, 95% CI, 1.47–25.7), axial enthesopathy count (OR 1.17 95% CI, 1.03–1.33). This study provides insight into the differences between nr-axSpA and r-axSpA in Mexico. Patients with r-axSpA were mainly male, with a younger presentation age, a higher prevalence of HLA-B27, more history of uveitis, fewer episodes of dactylitis, more axial enthesopathy, and higher disease activity than nr-axSpA.
- Open Access
- 1 April 2024
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 51 (6) , 563-576
Pan American League of Associations for Rheumatology Recommendations for the Treatment of Psoriatic Arthritis
Objective: Psoriatic arthritis (PsA) is chronic disease that compromises multiple domains and might be associated with progressive joint damage, increased mortality, functional limitation, and considerably impaired quality of life. Our objective was to generate evidence-based recommendations on the management of PsA in Pan American League of Associations for Rheumatology (PANLAR) countries.Methods: We used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)-ADOLOPMENT approach to adapt the 2019 recommendations of the European Alliance of Associations for Rheumatology. A working group consisting of rheumatologists from various countries in Latin America identified relevant topics for the treatment of PsA in the region. The methodology team updated the evidence and synthesized the information used to generate the final recommendations. These were then discussed and defined by a panel of 31 rheumatologists from 15 countries.Results: Theses guidelines report 15 recommendations addressing therapeutic targets, use of antiinflammatory agents and corticosteroids, treatment with disease-modifying antirheumatic drugs (conventional synthetic, biologic, and targeted synthetic), therapeutic failure, optimization of biologic therapy, nonpharmacological interventions, assessment tools, and follow-up of patients with PsA.Conclusion: Here we present a set of recommendations to guide decision making in the treatment of PsA in Latin America, based on the best evidence available, considering resources, medical expertise, and the patient's values and preferences. The successful implementation of these recommendations should be based on clinical practice conditions, healthcare settings in each country, and a tailored evaluation of patients.
- 1 April 2024
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 51 (6) , 563-576
Open AccessPan American League of Associations for Rheumatology Recommendations for the Treatment of Psoriatic Arthritis
Objective: Psoriatic arthritis (PsA) is chronic disease that compromises multiple domains and might be associated with progressive joint damage, increased mortality, functional limitation, and considerably impaired quality of life. Our objective was to generate evidence-based recommendations on the management of PsA in Pan American League of Associations for Rheumatology (PANLAR) countries.Methods: We used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)-ADOLOPMENT approach to adapt the 2019 recommendations of the European Alliance of Associations for Rheumatology. A working group consisting of rheumatologists from various countries in Latin America identified relevant topics for the treatment of PsA in the region. The methodology team updated the evidence and synthesized the information used to generate the final recommendations. These were then discussed and defined by a panel of 31 rheumatologists from 15 countries.Results: Theses guidelines report 15 recommendations addressing therapeutic targets, use of antiinflammatory agents and corticosteroids, treatment with disease-modifying antirheumatic drugs (conventional synthetic, biologic, and targeted synthetic), therapeutic failure, optimization of biologic therapy, nonpharmacological interventions, assessment tools, and follow-up of patients with PsA.Conclusion: Here we present a set of recommendations to guide decision making in the treatment of PsA in Latin America, based on the best evidence available, considering resources, medical expertise, and the patient's values and preferences. The successful implementation of these recommendations should be based on clinical practice conditions, healthcare settings in each country, and a tailored evaluation of patients.
- Open Access
- 8 August 2022
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 24 (1) , 1-11
A randomized, double-blind, placebo-controlled 12-week trial of infliximab in patients with juvenile-onset spondyloarthritis
Objective: To assess the efficacy and safety of infliximab versus placebo in the treatment of patients with juvenile-onset spondyloarthritis (JoSpA).Methods: Phase III, randomized, double-blind, placebo-controlled trial of 12 weeks that included patients ≤ 18 years old with JoSpA not responding to nonsteroidal anti-inflammatory drugs, sulfasalazine, or methotrexate. Patients were randomly assigned 1:1 to the infusion of infliximab 5mg/kg or placebo; completers entered then an open-label extension (OLE) period of 42 weeks. The primary endpoint was the number of active joints. Secondary outcomes included the assessment of disease activity, tender entheses, spinal mobility, serum C-reactive protein (CRP), the Bath Ankylosing Spondylitis Disease Activity and Functional Index, and the Childhood Health Assessment Questionnaire (CHAQ).Results: We randomized 12 patients to infliximab and 14 to placebo. No significant differences were found between groups at baseline. At week 12, the mean number of active joints was 1.4 (SD 2.4) in the infliximab group and 4.1 (SD 3.0) in the placebo group (p= 0.0002). A repeated-measures mixed model analysis that included all endpoints in the study demonstrated sustained favourable outcomes of infliximab for active joints, tender joints, swollen joints, and tender enthesis counts, as well as for CHAQ and CRP (p< 0.01). Adverse events were more frequent in the infliximab group, including infections and infusion reactions, but none of them was serious.Conclusion: Infliximab is efficacious for patients with JoSpA with an inadequate response to conventional treatment. No serious adverse events with the use of infliximab were observed.
- 8 August 2022
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 24 (1) , 1-11
Open AccessA randomized, double-blind, placebo-controlled 12-week trial of infliximab in patients with juvenile-onset spondyloarthritis
Objective: To assess the efficacy and safety of infliximab versus placebo in the treatment of patients with juvenile-onset spondyloarthritis (JoSpA).Methods: Phase III, randomized, double-blind, placebo-controlled trial of 12 weeks that included patients ≤ 18 years old with JoSpA not responding to nonsteroidal anti-inflammatory drugs, sulfasalazine, or methotrexate. Patients were randomly assigned 1:1 to the infusion of infliximab 5mg/kg or placebo; completers entered then an open-label extension (OLE) period of 42 weeks. The primary endpoint was the number of active joints. Secondary outcomes included the assessment of disease activity, tender entheses, spinal mobility, serum C-reactive protein (CRP), the Bath Ankylosing Spondylitis Disease Activity and Functional Index, and the Childhood Health Assessment Questionnaire (CHAQ).Results: We randomized 12 patients to infliximab and 14 to placebo. No significant differences were found between groups at baseline. At week 12, the mean number of active joints was 1.4 (SD 2.4) in the infliximab group and 4.1 (SD 3.0) in the placebo group (p= 0.0002). A repeated-measures mixed model analysis that included all endpoints in the study demonstrated sustained favourable outcomes of infliximab for active joints, tender joints, swollen joints, and tender enthesis counts, as well as for CHAQ and CRP (p< 0.01). Adverse events were more frequent in the infliximab group, including infections and infusion reactions, but none of them was serious.Conclusion: Infliximab is efficacious for patients with JoSpA with an inadequate response to conventional treatment. No serious adverse events with the use of infliximab were observed.
- Open Access
- 2 March 2022
- Published by Springer Nature in Research Square
A randomized, double-blind, placebo-controlled 12-Week trial of Infliximab in patients with Juvenile-Onset Spondyloarthritis or Enthesitis Related Arthritis
Objective. To assess the efficacy and safety of infliximab versus placebo in the treatment of patients with Juvenile-onset Spondyloarthritis and enthesitis-related arthritis (JoSpA/ERA). Methods. Phase III, randomised, double-blind, placebo-controlled-trial of 12-weeks that included patients Results. We randomized 12 patients to Infliximab and 14 to placebo. No significant differences were found between groups at baseline. At week 12, the mean number of active joints was 1.4 (SD 2.4) in the Infliximab group and 4.1 (SD 3.0) in the placebo group (p=0.0002). A repeated measures mixed model analysis that included all endpoints in the study demonstrated sustained favourable outcomes of Infliximab for active joints, tender joints, swollen joints and tender entheses counts, as well as for CHAQ and CRP (pConclusion. Infliximab is efficacious for patients with JoSpA/ERA with an inadequate response to conventional treatment. No serious adverse events with the use of infliximab were observed.
- 2 March 2022
- Published by Springer Nature in Research Square
Open AccessA randomized, double-blind, placebo-controlled 12-Week trial of Infliximab in patients with Juvenile-Onset Spondyloarthritis or Enthesitis Related Arthritis
Objective. To assess the efficacy and safety of infliximab versus placebo in the treatment of patients with Juvenile-onset Spondyloarthritis and enthesitis-related arthritis (JoSpA/ERA). Methods. Phase III, randomised, double-blind, placebo-controlled-trial of 12-weeks that included patients Results. We randomized 12 patients to Infliximab and 14 to placebo. No significant differences were found between groups at baseline. At week 12, the mean number of active joints was 1.4 (SD 2.4) in the Infliximab group and 4.1 (SD 3.0) in the placebo group (p=0.0002). A repeated measures mixed model analysis that included all endpoints in the study demonstrated sustained favourable outcomes of Infliximab for active joints, tender joints, swollen joints and tender entheses counts, as well as for CHAQ and CRP (pConclusion. Infliximab is efficacious for patients with JoSpA/ERA with an inadequate response to conventional treatment. No serious adverse events with the use of infliximab were observed.